Patents by Inventor Weiguang Zeng
Weiguang Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240050364Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: October 10, 2023Publication date: February 15, 2024Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Patent number: 11786458Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: May 24, 2022Date of Patent: October 17, 2023Assignee: ENA RESPIRATORY PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Publication number: 20230257345Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: ApplicationFiled: March 23, 2023Publication date: August 17, 2023Inventors: Ian Holmes, Weiguang Zeng, David Jackson, Christophe Demaison, Grant McLachlan
-
Publication number: 20220388950Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: ApplicationFiled: June 26, 2020Publication date: December 8, 2022Inventors: Ian Holmes, Weiguang Zeng, David Jackson, Christophe Demaison, Grant Mclachlan
-
Publication number: 20220296505Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: May 24, 2022Publication date: September 22, 2022Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Patent number: 11351114Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: July 26, 2019Date of Patent: June 7, 2022Assignee: ENA THERAPEUTICS PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Publication number: 20210230217Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: ApplicationFiled: December 21, 2018Publication date: July 29, 2021Inventors: David Jackson, Ian Holmes, Weiguang Zeng, Christophe Demaison
-
Publication number: 20200147028Abstract: The present invention relates to methods, compositions and kits for the treatment or prevention of respiratory conditions. In particular, the methods, compositions and kits are particularly useful, but not limited to, the prevention and/or treatment of rhinovirus infection and the prevention and/or treatment of asthma exacerbation. The invention provides a method inhibiting a rhinovirus infection in a subject comprising administering a composition consisting of a compound comprising a TLR2 agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 29, 2018Publication date: May 14, 2020Inventors: Nathan BARTLETT, Jason GIRKIN, David JACKSON, Weiguang ZENG, Ian HOLMES, Christophe DEMAISON
-
Publication number: 20190380952Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: July 26, 2019Publication date: December 19, 2019Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Patent number: 10406100Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: May 16, 2017Date of Patent: September 10, 2019Assignee: ENA THERAPEUTICS PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Patent number: 9889195Abstract: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.Type: GrantFiled: January 22, 2015Date of Patent: February 13, 2018Assignee: INNAVAC PTY LTDInventors: David Charles Jackson, Weiguang Zeng, Brendon Yew Loong Chua
-
Publication number: 20170246312Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: May 16, 2017Publication date: August 31, 2017Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Patent number: 9676819Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: September 22, 2011Date of Patent: June 13, 2017Assignee: INNAVAC PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Patent number: 9340622Abstract: The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. wherein, X1=a promiscuous CD4 T helper epitope selected from SEQ ID No.Type: GrantFiled: September 14, 2011Date of Patent: May 17, 2016Assignees: Council of Scientific & Industrial Research, University of MelbourneInventors: Javed N. Agrewala, Uthaman Gowthaman, David Jackson, Weiguang Zeng
-
Patent number: 9089508Abstract: The present invention relates to the targeted delivery of molecules to cells expressing toll-like receptors (TLRs). Aspects of the invention provide compounds comprising a positively charged group linked to a TLR ligand. These compounds are useful for in vitro and in vivo methods of transfection of TLR-expressing cells. Other aspects of the invention relate to the use of such compounds for repression of gene expression and DNA vaccination approaches.Type: GrantFiled: October 9, 2008Date of Patent: July 28, 2015Assignee: The University of MelbourneInventors: David Charles Jackson, Weiguang Zeng, Brendon Yew Loong Chua
-
Publication number: 20150150966Abstract: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.Type: ApplicationFiled: January 22, 2015Publication date: June 4, 2015Inventors: DAVID CHARLES JACKSON, WEIGUANG ZENG, BRENDON YEW LOONG CHUA
-
Patent number: 8986700Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.Type: GrantFiled: October 8, 2010Date of Patent: March 24, 2015Assignee: The Council of the Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng
-
Publication number: 20130230544Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: September 22, 2011Publication date: September 5, 2013Applicant: THE UNIVERSITY OF MELBOURNEInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Publication number: 20130183377Abstract: The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity.Type: ApplicationFiled: September 14, 2011Publication date: July 18, 2013Applicants: UNIVERSITY OF MELBOURNE, COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Javed Naim Agrewala, Uthaman Gowthaman, David Jackson, Weiguang Zeng
-
Patent number: 8367067Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope.Type: GrantFiled: June 19, 2009Date of Patent: February 5, 2013Assignee: The Council of the Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng